A virus-based vaccine may prevent cervical cancer
- 1 April 2005
- journal article
- research article
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 7 (2) , 125-131
- https://doi.org/10.1007/s11908-005-0072-3
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteersVaccine, 2003
- Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic PlantsJournal of Virology, 2003
- A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccineInternational Journal of Cancer, 2003
- Cellular Immune Responses to Human Papillomavirus (HPV)–16 L1 in Healthy Volunteers Immunized with Recombinant HPV‐16 L1 Virus‐Like ParticlesThe Journal of Infectious Diseases, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysisBritish Journal of Cancer, 2003
- Seroprevalence of Human Papillomavirus Type 16 Infection in the United StatesThe Journal of Infectious Diseases, 2002
- Route of administration of chimeric BPV1 VLP determines the character of the induced immune responsesImmunology & Cell Biology, 2002
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI Journal of the National Cancer Institute, 1995
- Synthesis and assembly of infectious bovine papillomavirus particles in vitroJournal of General Virology, 1993